Product Images Inspra

Not available.*

Reduction in SBP (mmHg) Study 1 and Study 2 with INSPRA (mg/day). The data includes a dosage range from 50 to 200 mg/day in Study 2.*

Reduction in DBP (mm Hg) of up to 10 points with the medication INSPRA at a dosage of 150 mg/day. The study compared different dosing regimens (Study 1 QD, Study 2 QD, Study 2 BID) showing improvements in blood pressure levels.*

This text provides information related to total number of events, patients, demographics (age, gender, race), medical history (diabetes, hypertension), Killip Class, creatinine clearance, use of medications (beta blockers, ACE inhibitors, Digoxin, diuretics), and a comparison of outcomes between Eplerenone group and Placebo group with the Hazard Ratio and 95% Confidence Interval.*

This text provides information about eplerenone tablets, a medication used for certain heart conditions. The tablets are to be stored at a temperature range of 15-30°C (50-86°F) and dispensed in child-resistant containers. Each tablet contains 25 mg of eplerenone. For more details on dosage and use, refer to the accompanying prescribing information. The product is distributed by Viatris Specialty LLC from Morgantown, WV 26505 USA.*

This text appears to be a label for medication called INSPRA, containing eplerenone tablets with a dosage of 50 mg. It provides storage instructions, NDC number, and the distributor information as Viaris Specialty LLC. The medication should be stored at 25-30°C (59-86°F) temperature range. It is available in child-resistant containers and comes in 30 tablet packs. For full prescribing information, further details are available.*